Johnson & Johnson (JNJ) announced on Wednesday a strategic deal with Sail Biomedicines to advance in vivo CAR-T therapies for immune-mediated diseases, along with an option to acquire Sail for $2.58B.
The company will make $785M in initial payments, including a $465M equity
Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.
